Pfizer Limited Reports Financial Results for Quarter Ended June 30, 2026
Pfizer Limited has released its unaudited financial results for the quarter ended June 30, 2026, detailing the company's performance across various periods. The results, which have been reviewed by statutory auditors B S R & Co. LLP, provide insight into income, expenses, and profitability for the period compared to previous quarters and full-year figures.The financial statements are presented in crore and show a diversified operational picture, with key metrics like revenue from operations and net profit being clearly detailed across the specified periods.
Financial Performance Overview (Amounts in Crore)
The following table presents the unaudited results for the quarter ended June 30, 2026, alongside audited figures from other relevant periods:| Particulars | 3 months ended 30/06/2026 (Unaudited) | 3 months ended 31/03/2026 (Audited) | Corresponding 3 months ended in previous year 30/06/2025 (Unaudited) | Previous year ended 31/03/2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 653.17 | 629.23 | 603.05 | 2,519.65 |
| Total income | 698.01 | 669.95 | 670.22 | 2,707.60 |
| Total expenses | 421.33 | 410.17 | 410.69 | 1,682.77 |
| Profit before tax and exceptional items | 276.68 | 259.78 | 259.53 | 1,024.83 |
| Net profit for the period/year | 204.47 | 199.82 | 191.75 | 722.43 |
| Total comprehensive income | 203.93 | 203.62 | 190.83 | 726.27 |
Insight into Expenses and Exceptional Items
The company noted specific circumstances related to expenses, particularly addressing exceptional items recorded in the previous financial year ended March 31, 2026. The exceptional items amounted to approximately 49.16 crore for that period. These charges included a personnel separation cost of approximately 41.73 crore relating to field force and marketing teams following an exclusive Supply and Marketing Agreement with Cipla Limited for four brand names: Corex Dx, Corex LS, Dolonex, and Neksium, in addition to costs for other support functions.Furthermore, the financial review noted that based on an assessment and legal opinion concerning the consolidation of existing labour laws into the 'New Labour Codes' by the Government of India (effective November 21, 2025), there was an increase in the provision for employee benefits amounting to approximately 117.43 crore for the year ended March 31, 2026 (nine months ended December 31, 2025).
The company operates solely within the 'Pharmaceuticals' segment and has no subsidiary, associate, or joint venture companies as of June 30, 2026.
PFIZER Stock Price Movement
As of 2:08 PM, Pfizer Limited shares are shedding 0.36%, trading at ₹4675.9 as the live market continues to move. The stock has ranged significantly today between a low of ₹4652.3 and a high of ₹4767.3, with 78,646 shares traded so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.